ArticleApplied sciences (Basel, Switzerland)2014
Radiosynthesis and
Article in Applied sciences (Basel, Switzerland), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Design, Synthesis and Evaluation of the First 2-Alkynyl(aza)indolePharmaceuticals (Basel, Switzerland) · 2025Article
- Advances in PET imaging of protein aggregates associated with neurodegenerative disease.Nature reviews. Neurology · 2025Review
- Development of Positron Emission Tomography Radiotracers for Imaging α-Synuclein Aggregates.Cells · 2025Review
- PET tracer development for imaging α-synucleinopathies.Archives of pharmacal research · 2025Review
- A promising PET tracer candidate targeting α-synuclein inclusions.Clinical and translational medicine · 2023Article
- Development of an α-synuclein positron emission tomography tracer for imaging synucleinopathies.Cell · 2023Article
- Multidimensional biomarkers for multiple system atrophy: an update and future directions.Translational neurodegeneration · 2023Review
- The Structural Combination of SIL and MODAG Scaffolds Fails to Enhance Binding to α-Synuclein but Reveals Promising Affinity to Amyloid β.Molecules (Basel, Switzerland) · 2023Article
- A review of the current research on in vivo and in vitro detection for alpha-synuclein: a biomarker of Parkinson's disease.Analytical and bioanalytical chemistry · 2023Review
- Translational molecular imaging and drug development in Parkinson's disease.Molecular neurodegeneration · 2023Review
- Multimodality imaging of neurodegenerative disorders with a focus on multiparametric magnetic resonance and molecular imaging.Insights into imaging · 2023Review
- Protein and Gene Delivery Systems for Neurodegenerative Disorders: Where Do We Stand Today?Pharmaceutics · 2022Review
- Radiolabelling small and biomolecules for tracking and monitoring.RSC advances · 2022Review
- The role of neuroimaging in Parkinson's disease.Journal of neurochemistry · 2021Review
- Alpha-Synuclein PET Tracer Development-An Overview about Current Efforts.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Lewy Body Dementias: A Coin with Two Sides?Behavioral sciences (Basel, Switzerland) · 2021Review
- Identification of a nanomolar affinity α-synuclein fibril imaging probe by ultra-high throughputChemical science · 2020Article
- Fluorine-18-Labeled Fluorescent Dyes for Dual-Mode Molecular Imaging.Molecules (Basel, Switzerland) · 2020Review
- Intramolecular Povarov Reactions for the Synthesis of Chromenopyridine Fused 2-Pyridone Polyheterocycles Binding to α-Synuclein and Amyloid-β Fibrils.The Journal of organic chemistry · 2020Article
- PET Radiopharmaceuticals for Alzheimer's Disease and Parkinson's Disease Diagnosis, the Current and Future Landscape.Molecules (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Two α-synuclein ligands, 3-methoxy-7-nitro-10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.